Core Points - Quest PharmaTech Inc. held its annual general meeting on August 25, 2025, where four directors were re-elected to the Board of Directors [1] - The company reported that approximately 50,288,000 shares were voted, representing about 29.7% of the eligible shares [2] - Quest granted 1,900,000 stock options to Directors and Officers at an exercise price of $0.05 per share, expiring in 10 years, pending TSX Venture Exchange approval [3] Company Overview - Quest PharmaTech Inc. is a Canadian biopharmaceutical company focused on developing products to enhance quality of life through proprietary technologies and investee companies [4] - The company is developing MAb-AR9.6, a theranostic agent targeting MUC16 for cancer, which is currently in late preclinical stage development [4] - Quest holds a 42.5% interest in OncoQuest Inc., which sold its immunotherapy technology assets in April 2020, and a 23% interest in OncoVent, a joint venture in China focused on antibody-based immunotherapeutic products for cancer [4]